BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 35330731)

  • 1. A Necroptosis-Related lncRNA-Based Signature to Predict Prognosis and Probe Molecular Characteristics of Stomach Adenocarcinoma.
    Luo L; Li L; Liu L; Feng Z; Zeng Q; Shu X; Cao Y; Li Z
    Front Genet; 2022; 13():833928. PubMed ID: 35330731
    [No Abstract]   [Full Text] [Related]  

  • 2. Establishment of a novel signature to predict prognosis and immune characteristics of pancreatic cancer based on necroptosis-related long non-coding RNA.
    Xiong Y; Kong X; Fang K; Sun G; Tu S; Wei Y; Ouyang Y; Wan R; Xiao W
    Mol Biol Rep; 2023 Sep; 50(9):7405-7419. PubMed ID: 37452900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer.
    Jin Y; Li J; Tang C; He K; Shan D; Yan S; Deng G
    Medicine (Baltimore); 2023 May; 102(18):e33664. PubMed ID: 37145007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel necroptosis-related long non-coding RNA signature predicts prognosis and immune response in cervical cancer patients.
    Kong X; Xiong Y
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):12947-12964. PubMed ID: 37466792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Necroptosis-Related lncRNA Signature Predicts the Prognosis of Lung Adenocarcinoma.
    Lu Y; Luo X; Wang Q; Chen J; Zhang X; Li Y; Chen Y; Li X; Han S
    Front Genet; 2022; 13():862741. PubMed ID: 35368663
    [No Abstract]   [Full Text] [Related]  

  • 6. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.
    Yang B; Wang Y; Liu T; Zhang M; Luo T
    Aging (Albany NY); 2024 Mar; 16(7):6098-6117. PubMed ID: 38546403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Necrotic related-lncRNAs: Prediction of prognosis and differentiation between cold and hot tumors in head and neck squamous cell carcinoma.
    Shi Y; Zhang Y; Zuo N; Wang L; Sun X; Liang L; Ju M; Di X
    Medicine (Baltimore); 2023 Jun; 102(23):e33994. PubMed ID: 37335630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer.
    Du X; Pu X; Wang X; Zhang Y; Jiang T; Ge Y; Zhu H
    Front Genet; 2022; 13():938250. PubMed ID: 36561319
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
    Han C; Zhang C; Wang H; Li K; Zhao L
    BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
    Song Z; Su M; Li X; Xie J; Han F; Yao J
    BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk between necroptosis-related lncRNAs to construct a novel signature and predict the immune landscape of lung adenocarcinoma patients.
    Wu J; Song D; Zhao G; Chen S; Ren H; Zhang B
    Front Genet; 2022; 13():966896. PubMed ID: 36186456
    [No Abstract]   [Full Text] [Related]  

  • 13. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
    Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
    Front Immunol; 2022; 13():854785. PubMed ID: 35392086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and validation of a glycolysis-related lncRNA signature for prognosis prediction in Stomach Adenocarcinoma.
    Liao T; Lu Y; Li W; Wang K; Zhang Y; Luo Z; Ju Y; Ouyang M
    Front Genet; 2022; 13():794621. PubMed ID: 36313430
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel necroptosis-related lncRNA signature for predicting prognosis and anti-cancer treatment response in endometrial cancer.
    He WP; Chen YY; Wu LX; Guo YY; You ZS; Yang GF
    Front Immunol; 2022; 13():1018544. PubMed ID: 36466815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Validation of Necroptosis-Related LncRNA Signature in Hepatocellular Carcinoma for Prognosis Estimation and Microenvironment Status.
    Chen C; Wu Y; Chen K; Xia Z; Liu X; Zhang C; Zhao H; Shen A
    Front Genet; 2022; 13():898507. PubMed ID: 35754846
    [No Abstract]   [Full Text] [Related]  

  • 17. Construction of a Necroptosis-Associated Long Non-Coding RNA Signature to Predict Prognosis and Immune Response in Hepatocellular Carcinoma.
    Wang W; Ye Y; Zhang X; Ye X; Liu C; Bao L
    Front Mol Biosci; 2022; 9():937979. PubMed ID: 35911976
    [No Abstract]   [Full Text] [Related]  

  • 18. The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma.
    He C; Zhu X; Kong F; Zhang X; Chai X; Zou C; Zhao D
    Biomed Res Int; 2022; 2022():2747799. PubMed ID: 35711526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma.
    Zeng C; Liu Y; He R; Lu X; Dai Y; Qi G; Liu J; Deng J; Lu W; Jin J; Liu Q
    Front Genet; 2022; 13():935056. PubMed ID: 36092903
    [No Abstract]   [Full Text] [Related]  

  • 20. A New Prognostic Signature Constructed with Necroptosis-Related lncRNA in Bladder Cancer.
    Yu Z; Lu B; Gao H; Liang R
    J Oncol; 2022; 2022():5643496. PubMed ID: 36425941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.